# US 2019/0375801 A1 · Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375801 A1
- Document ID: US20190375801A1
- Status: Published application
- Kind: A1
- Application number: 16/331,847
- Filed: 2017-09-08
- Published: 2019-12-12
- Earliest claimed: 2016-09-09
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Mark C. Poznansky; Jeffrey A. Gelfand
- Web page: https://patentgrep.com/patent/US20190375801A1

## CPC

- A61P 33/00: Antiparasitic agents
- C07K 14/35: from Mycobacteriaceae (F)
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/162: {from virus}
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure is directed to immune treatment of a disease (e.g., an infectious disease) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.

## Claims

### Claim 1

A method for treating a pathogen-related disease in a patient wherein said pathogen induces or expresses chemorepellant properties, the method comprising:
a) administering to the patient an effective amount of a fusion protein which fusion protein comprises a pathogen binding component and a stress protein component, wherein said pathogen binding component binds to the pathogen, pathogen-associated antigen, or a pathogen-infected cell and said stress protein component activates antigen-presenting cells; and
b) concurrently administering to said patient an effective amount of an anti-chemorepellant agent;
wherein the combination of the fusion protein and the anti-chemorepellant agent treat the pathogen-related disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-chemorepellant agent is selected from the group consisting of AMD3100 or a derivative thereof, AMD11070, AMD12118, AMD11814, AMD13073, FAMD3465, C131, BKT140, CTCE-9908, KRH-2731, TC14012, KRH-3955, BMS-936564/MDX-1338, LY2510924, GSK812397, KRH-1636, T-20, T-22, T-140, TE-14011, T-14012, TN14003, TAK-779, AK602, SCH-351125, tannic acid, NSC 651016, thalidomide, GF 109230X, an antibody that interferes with dimerization of a chemorepellant chemokine, and an antibody that interferes with dimerization of a receptor for a chemorepellant chemokine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the anti-chemorepellant agent is AMD3100.

### Claim 4 (depends on 1)

The method of claim 1, wherein the stress protein is HSP70 or an immune activating fragment and/or modified sequence thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the HSP70 or the immune activating fragment and/or modified sequence thereof is from Mycobacterium tuberculosis.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the pathogen binding component is an antibody or a fragment thereof, a single chain antibody, a variable domain, or a Fab domain.

### Claim at position 8

8-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, further comprising administering to the patient an effective amount of an anti-pathogen therapy that targets the pathogen.

### Claim 18

A pharmaceutical composition comprising a fusion protein and an anti-chemorepellant agent, said fusion protein comprising a pathogen binding component and a stress protein component.

### Claim 19 (depends on 18)

The composition of claim 18, further comprising antigen-presenting cells.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the antigen-presenting cells are dendritic cells.

### Claim 21 (depends on 18)

The composition of claim 18, wherein the anti-chemorepellant agent is selected from the group consisting of AMD3100 or a derivative thereof, AMD11070, AMD12118, AMD11814, AMD13073, FAMD3465, C131, BKT140, CTCE-9908, KRH-2731, TC14012, KRH-3955, BMS-936564/MDX-1338, LY2510924, GSK812397, KRH-1636, T-20, T-22, T-140, TE-14011, T-14012, TN14003, TAK-779, AK602, SCH-351125, tannic acid, NSC 651016, thalidomide, GF 109230X, an antibody that interferes with dimerization of a chemorepellant chemokine, and an antibody that interferes with dimerization of a receptor for a chemorepellant chemokine.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the anti-chemorepellant agent is AMD3100.

### Claim 23 (depends on 18)

The composition of claim 18, wherein the stress protein is HSP70 or an immune activating fragment and/or modified sequence thereof.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the HSP70 or the immune activating fragment and/or modified sequence thereof is from Mycobacterium tuberculosis.

### Claim 25 (depends on 18)

The composition of claim 18, wherein the pathogen binding component is an antibody or a fragment thereof, a single chain antibody, a variable domain, or a Fab domain.

### Claim at position 18

26-31. (canceled)

### Claim 32 (depends on 18)

The composition of claim 18, further comprising an anti-pathogen agent.

### Claim 33

A kit of parts for treatment of a pathogen-related disease in a patient, the kit comprising a therapeutically effective amount of an anti-chemorepellant agent and a fusion protein comprising a pathogen binding component and a stress protein component, wherein the pathogen binding component recognizes an antigen expressed by the pathogen or a cell infected by the pathogen.

### Claim 34 (depends on 33)

The kit of parts of claim 33, wherein the anti-chemorepellant agent is selected from the group consisting of AMD3100 or a derivative thereof, AMD11070, AMD12118, AMD11814, AMD13073, FAMD3465, C131, BKT140, CTCE-9908, KRH-2731, TC14012, KRH-3955, BMS-936564/MDX-1338, LY2510924, GSK812397, KRH-1636, T-20, T-22, T-140, TE-14011, T-14012, TN14003, TAK-779, AK602, SCH-351125, tannic acid, NSC 651016, thalidomide, GF 109230X, an antibody that interferes with dimerization of a chemorepellant chemokine, and an antibody that interferes with dimerization of a receptor for a chemorepellant chemokine.

### Claim 35 (depends on 34)

The kit of parts of claim 34, wherein the anti-chemorepellant agent is AMD3100.

### Claim 36 (depends on 33)

The kit of parts of claim 33, wherein the stress protein is HSP70 or an immune activating fragment and/or modified sequence thereof.

### Claim 37 (depends on 36)

The kit of parts of claim 36, wherein the HSP70 or the immune activating fragment and/or modified sequence thereof is from Mycobacterium tuberculosis.

### Claim 38 (depends on 33)

The kit of parts of claim 33, wherein the pathogen binding component is an antibody or a fragment thereof, a single chain antibody, a variable domain, or a Fab domain.

### Claim at position 26

39-41. (canceled)

### Claim 42 (depends on 33)

The kit of parts of claim 33, further comprising an anti-pathogen agent.